Skin clarity enhancing agent and food for enhancing skin clarity

Abstract

The present disclosure relates to a skin permeability improver comprising an extract extracted from a plant containing a rose anthocyanidin-based compound.

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480061758.8 (22) Application Date 2024.09.27 (30) Priority Data PCT / JP2023 / 035806 2023.09.29 JP (85) PCT International Application Entering National Phase Date 2026.03.26 (86) PCT International Application Application Data PCT / JP2024 / 034787 2024.09.27 (87) PCT International Application Publication Data WO2025 / 070773 JA 2025.04.03 (71) Applicant: Kin-In Co., Ltd. Address: Aichi Prefecture, Japan (72) Inventors: Daisuke Aoyagi, Yuki Ide, Isao Okushi, Yosuke Miura, Tomoe Kato (74) Patent Agency: Beijing Qingyihua Intellectual Property Agency (General Partnership) 11201 Patent Attorney: Rongbing Song (51) Int.Cl. A23L 33 / 105 (2006.01) A61K 8 / 9789 (2006.01) A61K 36 / 738 ​​(2006.01) (54) Invention Title: Skin Transparency Enhancer and Food for Enhancing Skin Transparency (57) Abstract: This disclosure relates to a skin transparency enhancer comprising an extract from a plant containing rose anthocyanin compounds. Claims 1 page, Description 11 pages, Drawings 9 pages, CN 121925188 A 2026.04.24 CN 1 21 92 51 88 A 1. A skin translucency enhancer, characterized in that it comprises an extract from a plant containing rose anthocyanin compounds. 2. The skin translucency enhancer according to claim 1, characterized in that it improves skin translucency by promoting blood circulation in the skin. 3. The skin translucency enhancer according to claim 1, characterized in that it improves skin translucency by reducing sebum secretion. 4. The skin translucency enhancer according to claim 2, characterized in that it improves skin dullness by promoting blood circulation in the skin. 5. The skin translucency enhancer according to claim 3, characterized in that it improves the visibility of skin pores by reducing sebum secretion. 6. The skin translucency enhancer according to any one of claims 1 to 5, characterized in that it is administered orally. 7. A food product for improving skin translucency, characterized in that it comprises a skin translucency enhancer according to any one of claims 1 to 5. 8. The skin translucency enhancer according to any one of claims 1 to 5, characterized in that the extract does not contain rose anthocyanin compounds.9. The skin translucency enhancer according to any one of claims 1 to 5, characterized in that the extract does not contain delphinidin compounds. Claims 1 / 1 page 2 CN 121925188 A Skin translucency enhancer and food for improving skin translucency

[0001] Cross-reference to related applications

[0002] This international application claims priority to international application PCT / JP2023 / 035806 filed with the Japan Patent Office on September 29, 2023, pursuant to the Patent Cooperation Treaty, the entire contents of which are incorporated herein by reference. Technical Field

[0003] This disclosure relates to a skin translucency enhancer and food for improving skin translucency. Background Art

[0004] In modern times, people's interest in maintaining beautiful skin is increasing. Skin translucency is one of the main factors in maintaining beautiful skin, and the demand for cosmetics and the like to achieve translucent skin is constantly increasing.

[0005] To improve skin translucency, various topical preparations have been developed to date. For example, Patent Document 1 discloses a skin translucency enhancer containing extracts of Lycium barbarum leaves and / or lotus germ extracts as active ingredients, which achieves the effect of improving skin translucency by inhibiting the carbonylation of stratum corneum proteins.

[0006] Prior Art Documents

[0007] Patent Documents

[0008] Patent Document 1: Japanese Patent Application Publication No. 2012-41276 Summary of the Invention

[0009] Technical Problem to be Solved by the Invention

[0010] The inventors have conducted extensive research on new substances that can improve skin translucency.

[0011] One aspect of this disclosure aims to provide a novel skin translucency enhancer.

[0012] Technical Solution to the Problem

[0013] One solution of this disclosure is a skin translucency enhancer comprising an extract from a plant containing a type of Rosacyanin compound.

[0014] According to one aspect of this disclosure, skin translucency can be improved by promoting blood circulation in the skin.

[0015] According to one aspect of this disclosure, skin translucency can be improved by reducing sebum secretion.

[0016] According to one aspect of this disclosure, skin dullness can be improved by promoting blood circulation in the skin.

[0017] According to one aspect of this disclosure, the visibility of skin pores can be improved by reducing sebum secretion.

[0018] According to one aspect of this disclosure, the skin translucency enhancer can be administered orally.

[0019] One aspect of this disclosure is a food product for improving skin translucency, comprising the above-mentioned skin translucency enhancer.

[0020] Effects of the Invention

[0021] According to the above-described configuration, a novel skin translucency enhancer can be provided.The aforementioned skin translucency enhancer is used to improve skin translucency, more preferably by promoting blood circulation in the skin and / or reducing sebum secretion. Specification 1 / 11 pages 3 CN 121925188 A Description of Drawings

[0022] Figure 1 is a graph showing the results of visual evaluation of skin translucency. It shows the change (%) in skin translucency in the test product intake group and the control product intake group after 4 weeks of ingestion of the test product or control product, with the pre-test skin translucency as 100%. This change is expressed as mean ± standard error (se).

[0023] Figure 2 is a graph showing the results of sebum measurement. It shows the change (%) in sebum amount in the test product intake group and the control product intake group after 4 weeks of ingestion of the test product or control product, with the pre-test sebum amount as 100%. This change is expressed as mean ± standard error.

[0024] Figure 3 is a graph showing the results of hemoglobin index measurement. Figure 4 shows the change (%) of hemoglobin index in the test group and control group 4 weeks after ingestion of the test product or control product, with the pre-test hemoglobin index as 100%. This change is expressed as mean ± standard error.

[0025] Figure 4 is a graph showing the measurement results of facial surface temperature. It shows the change (%) of surface temperature in the test group and control group 4 weeks after ingestion of the test product or control product, with the pre-test surface temperature as 100%. This change is expressed as mean ± standard error.

[0026] Figure 5 is a graph showing the measurement results of skin redness (a*). It shows the change of skin redness (a*) in the test group and control group 4 weeks after ingestion of the test product or control product, with the pre-test skin redness (a*) as 100%. This change is expressed as mean ± standard error.

[0027] Figure 6 is a graph showing the visual evaluation results of dullness. Figure 7 shows the change (%) in dullness in the test product intake group and the control product intake group after 4 weeks of test product or control product intake, with the pre-test dullness as 100%. The change is expressed as mean ± standard error.

[0028] Figure 7 is a graph showing the visual evaluation results of blackheads in pores. It shows the change (%) in blackheads in the test product intake group and the control product intake group after 4 weeks of test product or control product intake, with the pre-test blackheads as 100%. The change is expressed as mean ± standard error.

[0029] Figure 8A is a graph showing the analysis results of the total number of pores in a replicated image of the cheek. It shows the change (%) in the total number of pores in the test product intake group and the control product intake group after 4 weeks of test product or control product intake, with the pre-test total number of pores as 100%. The change is expressed as mean ± standard error.

[0030] Figure 8B is a graph showing the analysis results of the pore light and dark difference in a replicated image of the cheek. It shows the change (%) of pore light and dark difference in the test group and the control group after 4 weeks of ingestion of the test product or the control product, respectively, when the pore light and dark difference before the experiment is 100%. The change is expressed as mean ± standard error. Detailed Description

[0031] The skin translucency enhancement agent of this disclosure has an extract extracted from plants containing rose anthocyanin compounds.

[0032] Rosacyanin is a polyphenol found as a pigment in plants of the Rosaceae family. Examples of rose anthocyanin compounds include, for example, rose anthocyanin A1, rose anthocyanin B, and rose anthocyanin A2, but it is not limited thereto.

[0033] Examples of plants containing rose anthocyanin compounds include plants of the Rosaceae family, preferably plants of the Rosaceae family with purple / blue hues. In addition, in this disclosure, Rosaceae plants with purple / blue hues are also referred to as blue roses.Examples of Rosaceae plants with purple / blue hues include: Blue Sky, Ondina, Secret Parfum, Purple Fragrance, Charles de Gaulle, Silver Star (page 2 / 11, CN 121925188 A), Sterling Silver, Azure Dragon, Turn Blue, Novalis, Purple Time, Blue Bayou, Blue Moon, Blue Light, Blue River, Lovely Blue, Le Ciel Bleu, Blue Trail, Something Blue, Misty Purple, Rhapsody in Blue, Bleu Chateau, Purple Garden, Violet Hill, Blue Sky, Three Feathers, Waltz Time, Wisteria, Blue Paradise Heaven, Cool, Lapis Lazuli, Kinda Blue, Blue Gravity, Blue Angel, Purple Cloud, Melody Parfum, Angel Face, Prelude, Lady X, Grey Pearl, Lavender Pinocchio, Lilac Charm, Simone, Waltz Time, Glacier, Twilight, Ivory Tower, Kölner Karneval, Overture, Blue Monday, Cardinal de Richelieu, Stainless Steel, Grand Blue, News, Blue Ribbon, Blue Nile, Twilight, Madame Violet, Watarasawa, etc. As plants containing rose anthocyanin compounds, one of the above-mentioned plants can be used, or two, three, or more than four plants can be used in combination.Furthermore, the extraction raw materials are not limited to the aforementioned plants; all plants containing rose anthocyanin compounds can be used as extraction raw materials.

[0034] The extract obtained from plants containing rose anthocyanin compounds is an extract obtained from plants containing rose anthocyanin compounds by any method. As a specific example, the part of the plant used for extraction can be petals or other parts. In addition, the extract obtained from plants containing rose anthocyanin compounds may not need to contain rose anthocyanin compounds themselves, as long as the extract shows an effect of improving skin translucency. Furthermore, the extract obtained from plants containing rose anthocyanin compounds may not contain rosadelphin compounds.

[0035] The extract obtained from plants containing rose anthocyanin compounds can be obtained by conventional methods used for extracting plants.

[0036] Examples of extraction solvents include: water (including hot water), alcohols (e.g., methanol, anhydrous ethanol, ethanol and other lower alcohols, or polyols such as propylene glycol, 1,3-butanediol, glycerol, dipropylene glycol), ketones such as acetone, esters such as diethyl ether, dioxane, acetonitrile, ethyl acetate, xylene, benzene, chloroform and other organic solvents, animal oils, vegetable oils, supercritical carbon dioxide, and combinations of two or more of the above.

[0037] The extraction time can be, for example, 0.1 to 96 hours, but is not limited thereto. Furthermore, the extraction temperature can be, for example, 1 to 120°C, but is not limited thereto.

[0038] In addition, the extract of this disclosure includes, in addition to the extract obtained using plants as extraction raw materials, a diluted or concentrated extract, a dried extract, or any one of the crude or refined products described above. When drying the obtained extract, known drying methods (e.g., freeze drying, vacuum drying, and hot air drying) can be used. Furthermore, when purifying the obtained extract, known purification methods can be used (e.g., ion exchange resin treatment and activated carbon treatment).

[0039] The skin translucency enhancer of this disclosure is used to improve the translucency of the skin. In addition, the Japan Cosmetic Industry Association defines "skin translucency" as a state in which the skin is free of dullness and appears translucent.

[0040] In addition to visual inspection by experts, the translucency of the skin can also be evaluated using indicators such as light transmittance, image analysis, saturation, and hue angle. Specification 3 / 11 pages 5 CN 121925188 A

[0041] Furthermore, in this disclosure, the translucency of the skin can be improved by promoting blood circulation in the skin. Specifically, by promoting blood circulation in the skin, the oxyhemoglobin in the blood increases, resulting in a decrease in the absorption of red areas and an increase in red reflectance.Since there is a correlation between blood flow and the visual perception of dullness, dullness can be improved by promoting blood circulation. Furthermore, improving dullness can improve skin translucency, thereby enhancing skin clarity.

[0042] Additionally, the promotion of blood circulation can be evaluated using indicators such as the L* value (representing skin brightness), the a* value (representing skin redness), the hemoglobin index (representing the hemoglobin content in the skin), and the HbSO2 index (representing the proportion of oxyhemoglobin).

[0043] Therefore, another aspect of this disclosure is a blood circulation promoter comprising an extract from plants containing rose anthocyanin compounds. In addition to improving skin clarity, the blood circulation promoter of this disclosure can be used for various purposes related to promoting blood circulation.

[0044] Furthermore, another aspect of this disclosure is a body temperature elevator comprising an extract from plants containing rose anthocyanin compounds. Elevated body temperature promotes blood circulation in the skin. Therefore, it is expected to achieve the same effect as described above in improving skin clarity by promoting blood circulation.

[0045] In addition, the body temperature raising agent of this disclosure can be used for various purposes related to body temperature raising, in addition to improving skin transparency.

[0046] Furthermore, in this disclosure, skin transparency can be improved by reducing sebum secretion. Specifically, by reducing sebum secretion, the situation where pores become enlarged and round due to excessive sebum secretion can be suppressed. In addition, the situation where dirt accumulates in pores due to excessive sebum, resulting in keratin plugs, can be suppressed, and the situation where sebum oxidizes due to ultraviolet rays and forms blackheads can be suppressed. This can improve the visibility of skin pores. In addition, by improving the visibility of skin pores, the translucency of the skin can be improved, thereby improving the skin transparency.

[0047] Furthermore, the reduction of sebum secretion can be evaluated by indicators such as sebum amount and blackheads in pores, and the visibility of skin pores can be evaluated by indicators such as the average area, total number, standard deviation of angle, roundness, and light-dark difference of pores.

[0048] Therefore, another aspect of this disclosure can be a sebum secretion inhibitor comprising an extract from a plant containing rose anthocyanin compounds. In addition to improving skin translucency, the sebum secretion inhibitor of this disclosure can also be used for various purposes related to reducing sebum secretion.

[0049] The skin translucency enhancer of this disclosure can be included in food, cosmetics, pharmaceuticals, or quasi-pharmaceuticals.

[0050] The food form containing the skin translucency enhancer of this disclosure is arbitrary and not limited.Specific food forms can be listed as follows: ordinary food, ordinary beverage, supplements, health food, functional labeled food, specific health food and other health functional foods and specific purpose foods, soft drinks, tea drinks, health drinks, alcoholic beverages such as wine, pastries, rice, bread, noodles, cooked food, seasonings, etc.

[0051] In addition, there are no restrictions on the dosage form of cosmetics, pharmaceuticals and quasi-pharmaceuticals containing the skin translucency enhancer disclosed herein. Specific dosage forms of cosmetics, pharmaceuticals and quasi-pharmaceuticals can be listed as follows: capsules, tablets, powders, granules, liquids, emulsions, creams, gels, ointments, tablets, mousse, etc.

[0052] The content of the extract from plants containing rose anthocyanin compounds in the skin translucency enhancer can be 0.01 to 100% by weight, preferably 1 to 90% by weight, more preferably 5 to 80% by weight, and even more preferably 10 to 50% by weight, relative to 100% by weight of the skin translucency enhancer.

[0053] Furthermore, the content of the extract from plants containing rose anthocyanin compounds in the skin translucency enhancer, as specified in page 4 / 11 of CN 121925188 A, is most preferably 15-25% by weight, for example, 20% by weight, relative to 100% by weight of the skin translucency enhancer. By keeping the content of the extract from plants containing rose anthocyanin compounds in the skin translucency enhancer within this range, both the stickiness of the skin translucency enhancer can be suppressed, and the translucency of the skin can be effectively improved.

[0054] Furthermore, when the skin translucency enhancer of this disclosure is included in food, cosmetics, pharmaceuticals, or quasi-pharmaceuticals, the skin translucency enhancer may also be included in food, cosmetics, pharmaceuticals, or quasi-pharmaceuticals in the manner described above, as an extract from plants containing rose anthocyanin compounds.

[0055] Furthermore, any ingredient other than the extract from plants containing rose anthocyanin compounds may be added to the skin translucency enhancer. Examples of possible components include: substrate, solvent, preservative, oil, excipient, binder, disintegrant, preservative, coating agent, dispersant, fluidizing agent, stabilizer, flavoring agent, colorant, pH adjuster, surfactant, and fragrance.

[0056] The skin permeability enhancer of this disclosure can be administered to the subject in various forms of administration, preferably orally.

[0057] The dosage of the skin permeability enhancer of this disclosure is determined by considering the subject's age, gender, weight, method of use, dosage, etc. When administered orally, the daily dose of the extract from plants containing rose anthocyanin compounds in the skin permeability enhancer is preferably 0.1 mg / day to 500 mg / day, more preferably 1 mg / day to 250 mg / day, and more preferably 10 mg / day to 200 mg / day.By placing the dosage of the skin translucency enhancer within this numerical range, skin translucency can be effectively improved.

[0058] Furthermore, the skin translucency enhancer of this disclosure can be administered once or repeatedly over a long or short period of time. There is no limitation on the number of administrations; it can be three times a day, twice a day, once a day, once every two days, once every three days, once a week, once every two weeks, once a month, etc. Furthermore, there is no limitation on the duration of administration; it can be one day, two days, three days, one week, two weeks, four weeks, six months, one year, or longer.

[0059] Another aspect of this disclosure is a method for improving skin translucency, comprising administering to a subject a skin translucency enhancer comprising an extract derived from a plant containing rose anthocyanin compounds. Furthermore, another aspect of this disclosure relates to the use of extracts derived from plants containing rose anthocyanin compounds in the preparation of skin translucency enhancers.

[0060] [Example]

[0061] Example 1: Preparation of the formulation

[0062] Two types of blue roses cultivated by Kinsei Corporation of Japan were used as plants containing anthocyanin compounds. Five times the amount of water was added to a mixture of equal amounts of these blue rose petals (total petal weight: 4 kg), and the mixture was heated at 90-100°C for 2 hours, then pressed to obtain an extract. Dextrin (Max1000 (manufactured by Matsutani Chemical Industry Co., Ltd. of Japan)) was added to this extract at a solid content ratio of 1:4, and the mixture was freeze-dried to obtain an extract powder. Capsules containing this extract powder were prepared as test samples. The content of the extract (i.e., the extract) extracted from the plant containing anthocyanin compounds was 20% by weight relative to 100% by weight of the capsule. Furthermore, capsules containing only dextrin were prepared as a control.

[0063] Example 2: Various Experiments

[0064] Using the test articles and control articles prepared in Example 1, various experiments (hereinafter also referred to as "experiments") related to the improvement of the subjects' skin were conducted. Furthermore, the experimental plan and implementation followed the spirit of the Declaration of Helsinki (revised at the 2013 Fortaleza Conference), and were reviewed by the ethics review committee to ensure compliance with ethical and social considerations, and approved after confirming its reasonableness. The subjects were informed of the origin, purpose, methods, handling of personal information in the experimental results, the subjects' rights, and methods of consultation and compensation in the event of adverse events. The subjects were confirmed in writing that they voluntarily participated in the experiment, and the experiment was then implemented. In addition, any substantial deviation from the experimental plan required the approval of the ethics review committee.

[0065] (1) Selection of subjects

[0066] Forty-eight individuals who met the following selection criteria and did not violate the following exclusion criteria were selected as subjects of this trial through self-reporting.

[0067] Selection Criteria

[0068] • Healthy Japanese women aged 40 to 50 at the time of consent

[0069] • Individuals with skin type III or IV (according to Fitzpatrick's classification)

[0070] • Individuals who are aware of their dry skin

[0071] Exclusion Criteria

[0072] • Individuals with skin diseases such as psoriasis

[0073] • Individuals with skin diseases such as atopic dermatitis

[0074] • Individuals taking or applying medications that may affect the test results

[0075] • Individuals with contact allergies or who may experience allergic symptoms

[0076] • Individuals who currently visit a dermatologist regularly

[0077] • Individuals with eczema, rashes, sunburn, pigmentation, scratch marks, etc. at the test site

[0078] • Individuals who are pregnant or may be pregnant, or who are breastfeeding

[0079] • People who are participating in other trials that interfere with this trial at the start of the trial, or people who plan to participate in other trials that interfere with this trial during the scheduled period of the trial implementation.

[0080] • People with tattoos, body paint, or other tattoos on the test site.

[0081] • People who have received chemical peels, laser treatments, light therapy, skin injections, surgical treatments, or other cosmetic treatments on the test site within 4 weeks prior to the start of the trial.

[0082] • People deemed unsuitable to participate in the trial by the person in charge of the trial implementation, etc.

[0083] (2) Intake

[0084] Subjects were assigned to the test product intake group and the control product intake group using a stratified randomization method. Subjects ingested a prescribed dose (1 capsule) of the test product or control product before going to bed at night. The intake period was set at 4 weeks, and subjects took the test product or control product for 4 consecutive weeks.

[0085] (3) Evaluation or Measurement

[0086] In order to conduct intergroup comparisons between the test product intake group and the control product intake group, a double-blind method was used to conduct the trial. Evaluations or measurements were conducted twice: before the start of the trial and twice after four weeks of continuous use of the test or control product. Before the trial and after four weeks of continuous use of the test or control product, subjects cleansed their faces with makeup remover and facial cleanser, then sat quietly for approximately 20 minutes in a room maintained at a temperature of 21.0±0.3℃ and a relative humidity of 45.0±2.0%. After the skin had adapted to the test environment, the following evaluation items were assessed or measured.

[0087] • Evaluation of translucency using visual perception

[0088] • Sebum content

[0089] • Hemoglobin index measured using a colorimeter

[0090] • Body surface temperature

[0091] • Degree of skin redness (a*) measured using a colorimeter

[0092] • Evaluation of dullness using visual perception (instruction manual 6 / 11 pages 8 CN 121925188 A)

[0093] • Evaluation of blackheads and pores using visual perception

[0094] • Pore analysis using replicated images

[0095] (4) Changes / Missing data in measurement status

[0096] If a subject has the possibility of withdrawing from the trial due to health conditions or personal wishes, the health conditions and wishes of the subject will be given priority in accordance with the spirit of the Declaration of Helsinki. In addition, if certain data cannot be collected for the above or other reasons, such data will be treated as missing data.

[0097] In addition, if the following situations occur, the subject will be subject to the case discussion and will be excluded from the trial analysis (report) subjects without special reasons:

[0098] · The observation date is delayed by more than one week

[0099] · The subject is found to have seriously violated the instructions in the subject management matters during the trial

[0100] · The reliability of the data is seriously affected due to problems such as inspection

[0101] · The number of intake days (when the prescribed daily intake is not reached) exceeds 15% of the predetermined intake days

[0102] · The subject is found to be inconsistent with the selection criteria or to meet the exclusion criteria

[0103] · There are other clear reasons that are considered suitable for dropout treatment

[0104] (5) Statistical analysis

[0105] This trial started with 48 subjects and finally selected 44 subjects who did not drop out midway and did not meet the exclusion cases for exclusion from the analysis subjects as the analysis subjects. For reference, unpaired t-tests were used to perform statistical analysis on the test product intake group and control product intake group at each measurement period of the device measurement, and Wilcoxon rank-sum test was used to perform statistical analysis on the test product intake group and control product intake group at each measurement period.

[0106] (6) Results

[0107] (A) Evaluation of skin translucency by visual perception

[0108] After the skin adapted to the test environment, skilled evaluators visually evaluated the translucency of the subjects' facial skin and scored it using five levels (1: not felt at all, 2: almost not felt, 3: normal, 4: slightly felt, 5: very obvious). The results are shown in Figure 1. In addition, the larger the value in Figure 1, the higher the skin translucency.

[0109] Using the skin transparency as judged by visual perception before the experiment as 100%, the relative values ​​of skin transparency after 4 weeks of continuous use were compared. The results showed that the experimental product intake group had a trend difference and a higher value compared to the control product intake group. Therefore, it can be considered that the intake of the experimental product can improve the skin transparency.

[0110] (B) Sebum content

[0111] After the skin adapted to the test environment, the sebum content was measured using a Sebumeter SM815 (Courage+Khazaka, Germany). The results are shown in Figure 2. In addition, in Figure 2, the larger the value, the more sebum content there is.

[0112] Using the sebum content before the experiment as 100%, the relative values ​​of sebum content after 4 weeks of continuous use were compared. The results showed that the experimental product intake group had a significant difference and a lower value compared to the control product intake group. Therefore, it can be considered that the intake of the experimental product can reduce sebum content.

[0113] (C) Hemoglobin Index Measured Using a Colorimeter

[0114] After the skin adapted to the test environment, the hemoglobin index was measured using a CM-700d colorimeter (Konica Minolta, Japan). The results are shown in Figure 3. In addition, in Figure 3, a higher hemoglobin index value indicates more erythema on the skin or more blood flow (good blood circulation).

[0115] Using the hemoglobin index before the test as 100%, the relative values ​​of the hemoglobin index after 4 weeks of continuous use were compared. The results showed that the test product intake group had a significant difference and a higher value compared with the control product intake group. Therefore, it can be considered that the intake of product A on page 7 / 11 of the test instructions can promote blood circulation.

[0116] (D) Body Surface Temperature

[0117] After the skin adapted to the test environment, the facial body surface temperature was measured using a non-contact infrared thermometer (CISE, Muranaka Medical, Japan). The results are shown in Figure 4. In addition, the larger the value in Figure 4, the higher the body surface temperature.

[0118] With the body surface temperature before the experiment as 100%, the relative values ​​of body surface temperature after 4 weeks of continuous use were compared. The results showed that the experimental product intake group had a significant difference and a higher value compared with the control product intake group. Therefore, it can be considered that the intake of the experimental product can promote the increase of body surface temperature.

[0119] (E) Skin redness degree (a*) measured using a colorimeter

[0120] After the skin adapted to the test environment, the skin redness degree (a*) was measured using a colorimeter CM-700d (Konica Minolta, Japan). The results are shown in Figure 5. In addition, Figure 5 shows that the smaller the skin redness degree (a*), the less redness of the skin color.

[0121] With the skin redness degree (a*) before the experiment as 100%, the relative values ​​of skin redness degree (a*) after 4 weeks of continuous use were compared. The results showed that the experimental product intake group had a significant difference and a higher value compared with the control product intake group.Therefore, it can be considered that the intake of the test product can promote blood circulation.

[0122] (F) Evaluation of dullness by visual perception

[0123] After the skin adapted to the test environment, skilled evaluators visually evaluated the dullness of the subjects' facial skin and scored it using three levels (1: not dull, 2: hard to judge, 3: appears dull). The results are shown in Figure 6. In addition, the smaller the value in Figure 6, the less dull the skin.

[0124] Taking the dullness of the skin by visual perception as 100%, the relative values ​​of skin dullness after 4 weeks of continuous use were compared. The results showed that the test product intake group tended to have a lower value compared with the control product intake group. Therefore, it can be considered that the intake of the test product may improve dullness.

[0125] (G) Evaluation of blackheads in pores using visual perception

[0126] After the skin adapted to the test environment, skilled evaluators visually evaluated the blackheads in the pores of the subjects' facial skin and scored them using three levels (1: not obvious, 2: difficult to judge, 3: obvious). The results are shown in Figure 7. In addition, the smaller the value in Figure 7, the less obvious the blackheads in pores are.

[0127] Taking the blackheads in pores judged by visual perception as 100%, the relative values ​​of blackheads in pores after 4 weeks of continuous use were compared. The results showed that the test product intake group tended to have lower values ​​compared with the control product intake group. Therefore, it can be considered that the intake of the test product may improve blackheads in pores.

[0128] (H) Pore analysis using replicated images

[0129] After the skin adapted to the test environment, replicated images of the cheeks were obtained using SKIN CAST (Raptor Survey Institute, Japan) as a hydrophilic vinyl silicone imprinting agent, and the replicated images were photographed using i-Scope. The total number of pores and the difference in brightness in the captured images were analyzed using an image analysis application. In the experiment, pores with an area of ​​0.06 mm2 or larger were defined as pores. The total number of pores and the difference in brightness within the image analysis range (9.5 mm × 7.1 mm) were analyzed. The results are shown in Figures 8A and 8B. In addition, in Figures 8A and 8B, the smaller the value of the total number of pores, the fewer the pores. Furthermore, the smaller the value of the difference in brightness of the pores, the less noticeable the pores.

[0130] Taking the number of parts identified as pores in the captured images before the experiment as 100%, the relative value of the total number of pores after 4 weeks of continuous use was compared. The results showed that the experimental group had a significant difference and a lower value compared with the control group.

[0131] Furthermore, using the difference in pore brightness in the pre-test image as 100%, the relative value of the total number of pores after 4 weeks of continuous use was compared (see page 8 / 11 of the instruction manual, CN 121925188 A). The results showed that the test product intake group had a significant difference and a lower value compared to the control product intake group. Therefore, it can be considered that the intake of the test product helps to make pores less noticeable.

[0132] Example 3: Analysis of Extracts

[0133] The composition of the extract powder obtained from the plant containing rose anthocyanin compounds in Example 1 was analyzed.

[0134] (1) Measurement Conditions

[0135] <Dilution Ratio>

[0136] The extract powder obtained from the plant containing rose anthocyanin compounds was diluted to 20 mg / ml with ultrapure water (milliQ water) and measured. As a blank, ultrapure water (milliQ water) was used.

[0137] <LC-MS Conditions>

[0138] · Liquid Chromatograph

[0139] Separation column: ACQUITY UPLC BEH C18, 1.7 μm, 2.1 mm × 75 mm

[0140] Mobile phase A: 0.1% formic acid - ultrapure water

[0141] Mobile phase B: 0.1% formic acid - acetonitrile

[0142] Gradient: 5% B (0 min) ~ 98% B (10 min - 15 min)

[0143] Flow rate: 0.5 mL / min

[0144] Injection volume: 1 μL

[0145] Thermostat: 40 °C

[0146] · Mass Spectrometer

[0147] Ion source (Ion Source): ESI - positive, ESI - negative

[0148] Nebulizer: 2.5 bar

[0149] Dry gas: 8.0 L / min

[0150] Dry temperature (Dry Temp): 200 °C

[0151] Mass range (Mass Range): m / z 100 - 3000

[0152] (2) Results

[0153] The results are shown in Table 1 below.

[0154] [Table 1] Page 9 / 11 of the specification 11 CN 121925188 A

[0155]

[0156] Quality analysis was performed on the extract powder obtained from the plant containing rose anthocyanin compounds, and many peaks were observed. In addition, the compounds predicted according to each mass were estimated (refer to "Prediction" in Table 1). In the negative mode measurement, multiple divalent ions (2 -) were observed. In both the positive and negative modes, ions showing very similar m / z were sometimes observed at multiple time periods, indicating the existence of structural isomers.

[0157] Furthermore, the mass (m / z, mass-to-charge ratio) of the rose anthocyanin compounds (specifically rose anthocyanin A1, rose anthocyanin B, and rose anthocyanin A2) and the delphinidin compounds (specifically delphinidin A1, delphinidin B, and delphinidin A2) is shown in Table 2 below. Additionally, the mass (m / z, mass-to-charge ratio) of the rose anthocyanin compounds is referenced in Yuko Fukui et al. Tetrahedron Letters 43, 2637-2639, (2002) and Yuko Fukui et al. ScienceDirect Tetrahedron 62, 9661-9670, (2006). Furthermore, the mass-to-charge ratio (m / z) of the delphinidin compounds is referenced in International Publication No. 2015 / 178358.

[0158] [Table 2]

[0159]

[0160] The results of the quality analysis showed that no components with the same mass (m / z) as the rose anthocyanins and delphinidin compounds were detected in the extract powder extracted from plants containing rose anthocyanin compounds. That is, this indicates that the extract powder extracted from plants containing rose anthocyanins does not contain rose anthocyanins and delphinidin compounds. Furthermore, the test results in Example 2 above indicate that the effect should be attributed to one or more components in the extract powder extracted from plants containing rose anthocyanins that are different from the rose anthocyanins and delphinidin compounds. Instruction manual page 11 / 11, 13 CN 121925188 A, Figure 1; Instruction manual figure 1 / 9, page 14 CN 121925188 A, Figure 2; Instruction manual figure 2 / 9, page 15 CN 121925188 A, Figure 3; Instruction manual figure 3 / 9, page 16 CN 121925188 A, Figure 4; Instruction manual figure 4 / 9, page 17 CN 121925188 A, Figure 5; Instruction manual figure 5 / 9, page 18 CN 121925188 A, Figure 6; Instruction manual figure 6 / 9, page 19 CN 121925188 A, Figure 7; Instruction manual figure 7 / 9, page 20 CN 121925188 A, Figure 8A; Instruction manual figure 8 / 9, page 21 CN 121925188 A, Figure 8B; Instruction manual figure 9 / 9, page 22 CN 121925188 A.

Claims

1. A skin translucency enhancement agent, characterized in that, It contains extracts derived from plants containing anthocyanin compounds.

2. The skin translucency enhancement agent according to claim 1, characterized in that, Improve skin's radiance by promoting blood circulation.

3. The skin translucency enhancement agent according to claim 1, characterized in that, Improve skin's radiance by reducing sebum secretion.

4. The skin translucency enhancement agent according to claim 2, characterized in that, Improve dull skin by promoting blood circulation.

5. The skin translucency enhancement agent according to claim 3, characterized in that, Improve the visibility of skin pores by reducing sebum secretion.

6. The skin translucency enhancement agent according to any one of claims 1 to 5, characterized in that, The skin radiance enhancer is administered orally.

7. A food product for improving skin radiance, characterized in that, The product comprises the skin translucency enhancer as described in any one of claims 1 to 5.

8. The skin translucency enhancement agent according to any one of claims 1 to 5, characterized in that, The extract does not contain rose anthocyanin compounds.

9. The skin translucency enhancement agent according to any one of claims 1 to 5, characterized in that, The extract does not contain delphinidin compounds.

Images